Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse |
| |
| Affiliation: | 1. Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China;2. Guangdong South China Vaccine, Guangzhou, China;3. Sino-French Hoffmann Institute of Immunology, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou, China;4. Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China |
| |
| Abstract: | ![]()
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design. |
| |
| Keywords: | SARS-CoV-2 Intranasal administration Mucosal immunity Neutralizing antibody |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
